社区集群随机试验:年度与半年一次单剂伊维菌素联合阿苯达唑抗班氏吴策线虫感染
该研究为在加纳淋巴丝虫病流行社区开展的集群随机试验方案,比较每年一次与每半年一次单剂伊维菌素联合阿苯达唑 mass drug administration 对班氏吴策线虫感染率的影响。主要结局为通过四次横断面调查评估的感染率,同时进行昆虫学评估和成本效果分析。研究旨在检验半年一次治疗可加速持续传播地区淋巴丝虫病阻断的假说。
要点
- 研究比较每年一次与每半年一次伊维菌素联合阿苯达唑 mass drug administration 对淋巴丝虫病感染率的影响。
- 主要结局为四次横断面调查评估的感染率,并开展昆虫学评估和成本效果分析。
- 研究假设半年一次治疗可加速持续传播地区淋巴丝虫病的阻断。
核心结论
- 研究旨在检验半年一次治疗可加速持续传播地区淋巴丝虫病阻断的假说。
- 预期该研究将为加纳及其他面临类似挑战或处于淋巴丝虫病消除规划初期的非洲国家提供替代干预策略的证据。
研究设计与样本
- 在加纳淋巴丝虫病流行社区开展集群随机试验。
- 干预为向整个流行社区每年一次或每半年一次提供 mass drug administration。
- 根据淋巴丝虫病患病率识别集群,将集群随机分配至两组:每年一次伊维菌素联合阿苯达唑治疗,或每年一次伊维菌素联合阿苯达唑治疗后6个月再增加一次 mass drug administration。
- 主要结局为通过四次横断面调查评估的淋巴丝虫病感染率。
- 在随机抽取的参与者子样本中纵向评估微丝蚴患病率。
关键数值与推荐
- 主要结局指标为淋巴丝虫病感染率,通过四次横断面调查评估。
- 将开展昆虫学评估以评价研究集群的传播强度。
- 将评估成本和成本效果。
- 将采用半结构化访谈、焦点小组讨论和利益相关者分析进行嵌套过程评价,调查每种实施系统的社区可接受性、可行性和扩大规模。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Global Programme for the Elimination of Lymphatic Filariasis (GPELF) has been in operation since the year 2000, with the aim of eliminating the disease by the year 2020, following five to six rounds of effective annual mass drug administration (MDA). The treatment regimen is ivermectin (IVM) in combination with diethylcarbamazine (DEC) or albendazole (ALB). In Ghana, MDA has been undertaken since 2001. While the disease has been eliminated in many areas, transmission has persisted in some implementation units that had experienced 15 or more rounds of MDA. Thus, new intervention strategies could eliminate residual infection in areas of persistent transmission and speed up the lymphatic filariasis (LF)-elimination process. This study, therefore, seeks to test the hypothesis that biannual treatment of LF-endemic communities will accelerate the interruption of LF in areas of persistent transmission. METHODS: A cluster randomised trial will be implemented in LF-endemic communities in Ghana. The interventions will be yearly or twice-yearly MDA delivered to entire endemic communities. Allocation to study group will be by clusters identified using the prevalence of LF. Clusters will be randomised to one of two groups: receiving either (1) annual treatment with IVM + ALB or (2) annual MDA with IVM + ALB, followed by an additional MDA 6 months later. The primary outcome measure is the prevalence of LF infection, assessed by four cross-sectional surveys. Entomological assessments will also be undertaken to evaluate the transmission intensity of the disease in the study clusters. Costs and cost-effectiveness will be evaluated. Among a random subsample of participants, microfilaria prevalence will be assessed longitudinally. A nested process evaluation, using semi-structured interviews, focus group discussions and a stakeholder analysis, will investigate the community acceptability, feasibility and scale-up of each delivery system. DISCUSSION: It is expected that this study will add to the existing evidence on the need for alternative intervention strategies for the elimination of LF in Ghana and in other African countries that are facing similar challenges or are at the beginning of their LF-elimination programmes. TRIAL REGISTRATION: ClinicalTrials.gov, ID: NCT03036059 . Registered on 26 January 2017. Pan African Clinical Trials Registry, ID: PACTR201702002012425 . Registered on 23 February 2017.
引用
- de Souza DK, Ahorlu CS, Adu-Amankwah S, et al. Community-based trial of annual versus biannual single-dose ivermectin plus albendazole against Wuchereria bancrofti infection in human and mosquito populations: study protocol for a cluster randomised controlled trial. Trials. 2017. PMID: 28969715. doi:10.1186/s13063-017-2196-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。